title: Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells.
abstract: OBJECTIVE
  The phosphoinositide 3-kinase (PI3K)/Akt pathway is frequently activated in human cancer and plays a crucial role in neuroblastoma biology. We were interested in gaining further insight into the potential of targeting PI3K/Akt signaling as a novel antiproliferative approach in neuroblastoma.
  
  
  METHODS
  The expression pattern and functions of class I(A) PI3K isoforms were investigated in tumor samples and cell lines. Effects on cell survival and downstream signaling were analyzed following down-regulation of p110alpha or p110delta in SH-SY5Y and LA-N-1 cells by means of RNA interference.
  
  
  RESULTS
  Overexpression of the catalytic p110delta and regulatory p85alpha isoforms was detected in a panel of primary neuroblastoma samples and cell lines, compared with normal adrenal gland tissue. Although down-regulation of either p110alpha or p110delta led to impaired cell growth, reduced expression of p110delta also had a selective effect on the survival of SH-SY5Y cells. Decreased levels of p110delta were found to induce apoptosis and lead to lower expression levels of antiapoptotic Bcl-2 family proteins. SH-SY5Y cells with decreased p110delta levels also displayed reduced activation of ribosomal protein S6 kinase in response to stimulation with epidermal growth factor and insulin-like growth factor-I.
  
  
  CONCLUSIONS
  Together, our data reveal a novel function of p110delta in neuroblastoma growth and survival.
authors.affiliation: Division of Clinical Chemistry and Biochemistry, University Children's Hospital Zurich, Zurich, Switzerland.
authors.forename: Danielle
authors.initials: D
authors.lastname: Boller
authors.forename: Alexander
authors.initials: A
authors.lastname: Schramm
authors.forename: Kathrin T
authors.initials: KT
authors.lastname: Doepfner
authors.forename: Tarek
authors.initials: T
authors.lastname: Shalaby
authors.forename: André O
authors.initials: AO
authors.lastname: von Bueren
authors.forename: Angelika
authors.initials: A
authors.lastname: Eggert
authors.forename: Michael A
authors.initials: MA
authors.lastname: Grotzer
authors.forename: Alexandre
authors.initials: A
authors.lastname: Arcaro
mesh_terms: D017209:Apoptosis / Q000502:physiology; D015153:Blotting, Western; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002470:Cell Survival / Q000502:physiology*; D002478:Cells, Cultured; D015870:Gene Expression; D020869:Gene Expression Profiling; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism; D009447:Neuroblastoma / Q000201:enzymology*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism*; D011494:Protein Kinases / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D058570:TOR Serine-Threonine Kinases
chemical_list: D007527:Isoenzymes; D019869:Phosphatidylinositol 3-Kinases; D011494:Protein Kinases; D019253:Proto-Oncogene Proteins c-bcl-2; D058570:TOR Serine-Threonine Kinases; C546842:MTOR protein, human